Project

Back to overview

Innovative adjuvanted influenza vaccines: a Swiss-Indonesian collaboration towards better pandemic influenza preparedness.

English title Innovative adjuvanted influenza vaccines: a Swiss-Indonesian collaboration towards better pandemic influenza preparedness.
Applicant Collin Nicolas
Number 160923
Funding scheme r4d (Swiss Programme for Research on Global Issues for Development)
Research institution Département de Biochimie Université de Lausanne
Institution of higher education University of Lausanne - LA
Main discipline Pharmacology, Pharmacy
Start/End 01.08.2016 - 31.03.2020
Approved amount 498'486.00
Show all

All Disciplines (3)

Discipline
Pharmacology, Pharmacy
Immunology, Immunopathology
Infectious Diseases

Keywords (5)

adjuvants; H5N1; vaccine; influenza; pandemic

Lay Summary (French)

Lead
Le risque pandémique lié à l’apparition d’un nouveau virus grippal pour l’homme est d’autant plus important dans les pays en voie de développement car de nombreux facteurs compliquant comme la malnutrition, la pauvreté ou l’accès limité aux soins y sont présents. Ce projet de recherche Suisse-Indonésie a pour but de développer un vaccin pandémique combiné à des technologies vaccinales modernes afin de protéger plus efficacement la population Indonésienne.
Lay summary
Les pandémies grippales sont des événements imprévisibles mais récurrents, qui peuvent avoir de graves conséquences de Santé Publique à travers le monde. Les vaccins inactivés (entiers et sous-unitaires) demeurent la stratégie la plus efficace pour prévenir et contenir les pandémies, mais leur développement ne peut débuter qu’en temps réel, quand la nouvelle souche virale est identifiée. Or les limites de la capacité actuelle de production de vaccins antigrippaux, la faible immunogénicité des souches de grippe pandémique (nécessitant à la fois de grande quantité d'antigènes et plusieurs injections pour protéger efficacement contre l’infection) sont autant de facteurs contraignants.

Dans ce projet de recherche Suisse-Indonésie, nous étudierons l'utilisation d'un vaccin entier inactivé (les vaccins entiers étant principalement produits par les pays en voie de développement) combiné à des technologies vaccinales modernes, afin de permettre de protéger les individus suite à une dose unique de vaccin et d’augmenter ainsi le nombre de doses de vaccins disponibles.

Nous explorerons différentes stratégies de formulation vaccinale avec ce vaccin entier afin d’améliorer son efficacité, en utilisant des combinaison d’adjuvants ainsi que des techniques d’encapsulation en microparticules. La plupart des pays en voie de développement n’ont pas d’accès direct aux technologies adjuvantes, ces connaissances théoriques et pratiques seront donc transférées vers l’Indonésie à travers une plate-forme de formulation vaccinale qui donnera accès à ces nouvelles technologies sur le long-terme pour les producteurs de vaccins et les groupes de recherche en Indonésie.
Direct link to Lay Summary Last update: 27.07.2016

Responsible applicant and co-applicants

Employees

Collaboration

Group / person Country
Types of collaboration
Vaccine Formulation Institute Switzerland (Europe)
- in-depth/constructive exchanges on approaches, methods or results
PT Bio Farma Indonesia (Asia)
- in-depth/constructive exchanges on approaches, methods or results
Geneva Antibody Facility Switzerland (Europe)
- Research Infrastructure
IZSVe Italy (Europe)
- Research Infrastructure
Merck Japan (Asia)
- Research Infrastructure
Jakarta facility (virus propagation) Indonesia (Asia)
- Research Infrastructure
PT Global Biosciences Technology Indonesia (Asia)
- Industry/business/other use-inspired collaboration
Brawijaya University Indonesia (Asia)
- Research Infrastructure
Industry partner (name not disclosed) France (Europe)
- Industry/business/other use-inspired collaboration
PT IPD Shigeta Indonesia (Asia)
- Industry/business/other use-inspired collaboration

Scientific events



Self-organised

Title Date Place
Vaccine Formulation Symposium 28.03.2017 Surabaya, Indonesia

Knowledge transfer events



Self-organised

Title Date Place
Ferret and liposome training 08.12.2019 PNF Facility Surabaya, Indonesia
Animal study training 30.09.2018 PNF Facility, Surabaya, Indonesia
Training visit II 13.07.2018 PNF Facility, Surabaya, Indonesia
Training visit 19.06.2018 University of Lausanne, Switzerland
Adjuvanted vaccine formulation workshop 30.03.2017 Surabaya, Indonesia

Communication with the public

Communication Title Media Place Year
Media relations: print media, online media PNF laboratory in the context of Covid-19 Kompas.TV News International 2020
Media relations: print media, online media PNF introducing the vaccine formulation laboratory in Indonesia Surabaya Tribune News International 2017

Abstract

Vaccination is the most effective strategy to prevent influenza pandemics but also to reduce the severity of illness and thereby the impact on public health. However “pre-pandemic vaccines” are of limited efficacy against new pandemics strains, due to the novelty of their surface antigens, and the lack of cross reactivity of the current vaccines. In a real-time pandemic situation, the production of a pandemic vaccine, specific to the circulating strain will take four to six months. However, due to the weak immunogenicity of pandemic influenza strains, vaccination requires a high amount of antigen and two injections, which causes major logistic and time challenges. This situation is even more critical in developing countries, where there is usually a lack of local production of influenza vaccine and a lack of access to modern vaccine technologies. In this proposal, we propose to explore the use of a Whole Inactivated Virion (WIV) influenza vaccine to develop innovative vaccine formulation solutions in order to allow a single shot vaccine strategy. We believe that this strategy can allow many more doses of influenza vaccines to be made available, and will reduce significatively the timeframe and efficacy of a response against pandemics.The WIV induces stronger immunogenicity than any other inactivated influenza vaccine, and is predominantly produced by Developing Countries Vaccine Manufacturers. However, it is still missing efficient and safe adjuvant technologies in order to allow its use with lower amount of antigen and, importantly its use through single-shot immunization.Within this Swiss-Indonesian research project, we will explore different formulation strategies, using combination of the promising immunomodulator QS-21, an adjuvant known to enhance both humoral and cell mediated immune responses, and the encapsulation of WIV into polymer microparticles in order to allow a single-shot immunization. In the first part of this project, vaccine formulations will be developed and characterized by the Swiss partners, and then in the second part the technology will be transferred to the Indonesian partners and tested in vivo in a mice and ferret model. Through this multidisciplinary collaboration, the aim is also to establish a sustainable vaccine formulation platform in Indonesia, in order to allow the access to these new enabling technologies in a place where it is critically needed.
-